Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-03-20 |
Kiadis Pharma (The Netherlands) |
|
|
nomination |
Cancer - Oncology - Hematological diseases |
Nomination |
2017-03-20 |
X-Chem (USA - MA) Astellas Pharma (Japan) |
|
|
research
collaboration |
|
Collaboration agreement |
2017-03-17 |
Daiichi Sankyo (Japan) Heptares Therapeutics (UK) |
G protein-coupled receptor (GPCR) |
pain |
research
development |
CNS diseases |
R&D agreement |
2017-03-17 |
AstraZeneca (UK) Circassia (UK) |
Tudorza® (aclidinium bromide inhalation powder) and Duaklir® (aclidinium bromide and formoterol) |
chronic obstructive pulmonary disease (COPD) |
development
commercialisation |
Lung diseases - Respiratory diseases |
Development agreement |
2017-03-16 |
Daiichi Sankyo (Japan) Mitsubishi UFJ Capital (Japan) National Institutes of Biomedical Innovation, Health and Nutrition (Japan) OiDE Adjubilee (Japan) |
|
|
research |
Cancer - Oncology |
R&D agreement |
2017-03-16 |
Kite Pharma (USA - CA) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-03-16 |
PTC Therapeutics (USA - NJ) Marathon Pharmaceuticals (USA - IL) |
Emflaza™ (deflazacort) |
Duchenne muscular dystrophy |
product acquisition |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Product acquisition |
2017-03-16 |
Biogen (USA - MA) |
|
|
nomination |
|
Nomination |
2017-03-16 |
Beactica (Sweden) Uppsala University (Sweden) SciLifeLab (Sweden) |
allosteric modulators of the epigenetic protein LSD1 |
glioma |
research - R&D |
Cancer - Oncology |
Research agreement |
2017-03-15 |
Adaptimmune (UK) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-03-14 |
AMO Pharma (UK) Ranedis Pharmaceuticals (USA - PA) |
RND-001 |
|
collaboration
development |
Rare diseases - Genetic diseases - CNS diseases -Neurodegenerative diseases |
Development agreement |
2017-03-14 |
Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (USA - MA) MaxCyte (USA - MD) |
|
CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined immunodeficiency |
licensing |
Hematologic diseases - Genetic diseases - Rare diseases - Immunological diseases |
Licensing agreement |
2017-03-14 |
Fortress Biotech (USA - NY) Cyprium Therapeutics (US - NY) |
Cyprium Therapeutics (US - NY) |
Menkes disease and related copper metabolism disorders |
establishment of a new subsidiary in the US |
Rare diseases - Genetic diseases - Metabolic diseases |
Establishment of a new subsidiary in the US |
2017-03-13 |
Celgene (USA - NJ) Agios Pharmaceuticals (USA -MA) |
metabolic immuno-oncology programs |
|
collaboration |
Cancer - Oncology |
Milestone |
2017-03-13 |
Mylan (USA - PA) Roche (Switzerland) |
MYL-1401O - biosimilar version of trastuzumab |
|
settlement - licensing |
Cancer - Oncology |
Licensing agreement |
2017-03-13 |
GlycoMimetics (USA - Md) |
|
|
nomination |
Cancer - Oncology |
Nomination |
2017-03-13 |
GSK (UK) |
Gödöll? plant in Hungary |
diphtheria, tetanus |
construction of new premises |
Infectious diseases |
Construction of new premises |
2017-03-10 |
Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA) |
novel T cell therapies |
|
R&D - research |
Cancer - Oncology |
Research agreement |
2017-03-10 |
Endocyte (USA - IN) Seattle Children's Research Institute (USA - WA) |
small molecule drug conjugates platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting |
|
development |
Cancer - Oncology |
Development agreement |
2017-03-09 |
Galapagos (Belgium) Pharnext (France) |
synergistic drug combinations |
neurodegenerative diseases, immunoinflammatory diseases |
research - R&D |
Neurodegenerative diseases - Neuroinflammatory diseases |
Research agreement |